Transcreener EPIGEN Methyltransferase FP Assay

The Transcreener^® HTS Assay platform overcomes the need for time-consuming, one-off assay development for individual members within a group transfer enzyme family by utilizing a single set of assay reagents that detect an invariant product. The generic nature of the Transcreener^® HTS Assay platform eliminates delays involved in assay development for new HTS targets, and greatly simplifies compound and inhibitor profiling across multiple target families. Transcreener assays have been validated with major HTS instruments to determine the optimal filters and settings for maximal assay performance. Application notes with all important details are available.

The Transcreener^® EPIGEN Methyltransferase assay is available in a fluorescence polarization (FP) readout, which provide a safe HTS-compatible alternative to cumbersome radioassay methods and are more sensitive and less subject to interference than other detection methods. The readout uses a far-red tracer to minimize compound interference and lower false-positive rates.

The Transcreener^® EPIGEN Methyltransferase FP Assay (Prod. No. BBL-3017) is a far-red, competitive fluorescence polarization (FP) assay. It combines the extensively validated Transcreener® AMP2/GMP2 Assay, which relies on fluorescent immunodetection of AMP, with coupling enzymes that convert SAH to AMP. The assay can be used with any enzymes that convert S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH). Examples include enzymes within the histone methyltransferase (HMT) and DNA methyltransferase (DNMT) families. The Transcreener^® EPIGEN Methyltransferase FP Assay is a simple one step homogenous detection assay, and is extremely flexible with regard to SAM concentrations (0.1 to 50 μM). The assay provides excellent quality with a Z’ = 0.7 and signal (≥100 mP polarization shift) at low substrate conversion using normal reaction conditions.